Erik Schwiebert, Ph.D.
Chief Executive Officer, Chief Scientific Officer, and Director

As Founder and Director, Erik focuses on overall leadership of DiscoveryBioMed, Inc. As CSO, he serves as the principal science consultant in client work and in managing the company's research and development. He brings several years of experience as a researcher in cell physiology and pathophysiology. He has focused on receptors and ion channels in human epithelial cells that regulate ion transport and that are pertinent to therapeutics for cystic fibrosis, polycystic kidney disease, and diabetes mellitus. He currently focuses his scientific efforts as an applied discovery scientist, applying his cell physiology and pathophysiology training to DBM programs. He was previously an Associate Professor with tenure at the University of Alabama at Birmingham. Prior to that, Erik was a postdoctoral fellow at the Johns Hopkins University School of Medicine. His education includes a PhD in Physiology from Dartmouth College and a BA in Biology from Grinnell College. Erik is originally from Princeton, NJ.

Eric Seales, Ph.D.
Chief Laboratory Officer

As Chief Laboratory Officer, Eric is responsible for managing a range of on-going research projects and specific initiatives within the company, as well as for overall laboratory management. He has established many of the 'high value' immortal human cell systems used by DBM in various applications. Dr. Seales brings industrial biotechnology experience with a number of applications, including 3-dimensional tissue modeling and in-vitro drug toxicity testing. His experience also includes a postdoctoral fellowship in osteoclast differentiation pathways in bone remodeling at the University of Alabama at Birmingham. He holds a BS in Physical Science from Auburn University and a doctorate in pathology from UAB, where he examined integrin-driven cell signaling and its role in cancer cell metastasis. He is very adept at bioassay design and optimization. Eric is originally from Montgomery, AL.

John H. Streiff, Ph.D.
Chief Cheminformatics Officer

As Chief Cheminformatics Officer, John serves as the company's specialist in pharmacology, molecular structure modeling, pharmacophore analysis, life science modeling, bioinformatics and cheminformatics. Not only is Dr. Streiff adept at finding 'commonality in structure' among DBM's validated hit compounds but he is also facile at conversion of HTS bioassays into automated and robotic formats. His previous experience includes research on molecular pharmacology of anestheic drugs at the University of Alabama at Birmingham and at Mayo Clinic where John was an Assistant Professor. Dr. Streiff's education includes a BS in Chemistry from the University of Northern Iowa and a PhD in Chemistry from the University of Idaho. John is originally from Rochester. MN